About SenzaGen AB 
SenzaGen AB
Pharmaceuticals & Biotechnology
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Company Coordinates 
Company Details
Medicon Village, Building 401, Scheelevagen 2 LUND None : 223 63
Registrar Details
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Management
Designation
Prof. Carl Borrebaeck
Chairman of the Board
Mr. Peter Nahlstedt
Acting Vice President Sales, Director
Dr. Anki Malmborg Hager
Director
Ms. Laura Chirica
Independent Director
Ms. Ann Gidner
Independent Director
Prof. Ian Kimber
Independent Director
Revenue and Profits:
Net Sales:
13 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
Pharmaceuticals & Biotechnology
SEK 193 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.32
-12.83%
2.60






